Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Rare, protein-truncating variants in ATM , CHEK2 and PALB2 , but not XRCC2 , are associated with increased breast cancer risks
Ist Teil von
Journal of medical genetics, 2017-11, Vol.54 (11), p.732-741
Ort / Verlag
England
Erscheinungsjahr
2017
Quelle
MEDLINE
Beschreibungen/Notizen
Breast cancer (BC) is the most common malignancy in women and has a major heritable component. The risks associated with most rare susceptibility variants are not well estimated. To better characterise the contribution of variants in
,
,
and
, we sequenced their coding regions in 13 087 BC cases and 5488 controls from East Anglia, UK.
Gene coding regions were enriched via PCR, sequenced, variant called and filtered for quality. ORs for BC risk were estimated separately for carriers of truncating variants and of rare missense variants, which were further subdivided by functional domain and pathogenicity as predicted by four
algorithms.
Truncating variants in
(OR=4.69, 95% CI 2.27 to 9.68),
(OR=3.26; 95% CI 1.82 to 6.46) and
(OR=3.11; 95% CI 2.15 to 4.69), but not
(OR=0.94; 95% CI 0.26 to 4.19) were associated with increased BC risk. Truncating variants in
and
were more strongly associated with risk of oestrogen receptor (ER)-positive than ER-negative disease, while those in
were associated with similar risks for both subtypes. There was also some evidence that missense variants in
,
and
may contribute to BC risk, but larger studies are necessary to quantify the magnitude of this effect.
Truncating variants in
are associated with a higher risk of BC than those in
or
. A substantial risk of BC due to truncating
variants can be excluded.